EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Throughput-scalable manufacturing of SARS-CoV-2 mRNA lipid nanoparticle vaccines

Sarah J Shepherd, Xuexiang Han, Alvin J Mukalel, Rakan El-Mayta iD, Ajay S Thatte, Jingyu Wu, Marshall S Padilla, Mohamad-Gabriel Alameh, Neha Srikumar, Daeyeon Lee, Drew Weissman, David Issadore und 1 weitere

Proceedings of the National Academy of Sciences · 15.08.2023 · 120 (33)

DOI: 10.1073/pnas.2303567120 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, online erschienen am 09.08.2023. Verfasst von Sarah J Shepherd und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Bioengineering, University of Pennsylvania, Philadelphia, PA 19104. Hauptthemen laut MEDLINE: COVID-19, Nanoparticles. Die Arbeit wurde bisher 147-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NHGRI NIH HHS, NIDCR NIH HHS, NIDDK NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lipid nanoparticles (LNPs) are a potent delivery technology that have made it possible for the recent clinical breakthroughs in mRNA therapeutics and vaccines. A key challenge to the broader implementation of mRNA therapeutics and vaccines is the development of technology to produce precisely defined LNP formulations, with throughput that can scale from discovery to commercial manufacturing and meet the stringent manufacturing standards of the pharmaceutical industry. To address these challenges, we have developed a microfluidic chip that incorporates 1×, 10×, or 256× LNP-generating units that achieve scalable production rates of up to 17 L/h of precisely defined LNPs. Using these chips, we demonstrate that LNP physical properties and potency in vivo are unchanged as throughput is scaled. Our chips are fabricated out of silicon and glass substrates, which have excellent solvent compatibility, compatibility with pharmaceutical manufacturing, and can be fully reset and reused. SARS-CoV-2 mRNA-LNP vaccines formulated by our chips triggered potent antibody responses in a preclinical study. These results demonstrate the feasibility of directly translating microfluidic-generated LNPs to the scale necessary for commercial production.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19NanoparticlesHumansSARS-CoV-2LiposomesRNA, Messenger

Stichwörter der Autor:innen

drug deliverymRNAnanomedicinenanoparticlevaccines

Substanzen

Lipid NanoparticlesLiposomesRNA, Messenger

Autor:innen und Institutionen

  • Department of Bioengineering, University of Pennsylvania, Philadelphia, PA 19104.
  • Department of Chemical and Biomolecular Engineering, University of Pennsylvania, Philadelphia, PA 19104.
  • Department of Medicine, University of Pennsylvania, Philadelphia, PA 19104.
  • Department of Biochemistry and Biophysics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104.
  • Department of Electrical and Systems Engineering, University of Pennsylvania, Philadelphia, PA 19104.
  • Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104.

ORCID-Profile: Rakan El-Mayta, Michael J Mitchell

Förderung

  • NHGRI NIH HHS
  • NIDCR NIH HHS
  • NIDDK NIH HHS
  • NHLBI NIH HHS
  • NCI NIH HHS
  • NCATS NIH HHS
  • NIGMS NIH HHS
  • HHS | National Institutes of Health

Zitieren

APA

Shepherd, S. J., Han, X., Mukalel, A. J., El-Mayta, R., Thatte, A. S., Wu, J., Padilla, M. S., Alameh, M. G., Srikumar, N., Lee, D., Weissman, D., Issadore, D., & Mitchell, M. J. (2023). Throughput-scalable manufacturing of SARS-CoV-2 mRNA lipid nanoparticle vaccines. Proceedings of the National Academy of Sciences, 120(33). https://doi.org/10.1073/pnas.2303567120

Vancouver

Shepherd SJ, Han X, Mukalel AJ, El-Mayta R, Thatte AS, Wu J, et al. Throughput-scalable manufacturing of SARS-CoV-2 mRNA lipid nanoparticle vaccines. Proceedings of the National Academy of Sciences. 2023;120(33). doi:10.1073/pnas.2303567120

BibTeX
@article{Shepherd2023,
  author = {Shepherd, Sarah J and Han, Xuexiang and Mukalel, Alvin J and El-Mayta, Rakan and Thatte, Ajay S and Wu, Jingyu and Padilla, Marshall S and Alameh, Mohamad-Gabriel and Srikumar, Neha and Lee, Daeyeon and Weissman, Drew and Issadore, David and Mitchell, Michael J},
  title = {Throughput-scalable manufacturing of SARS-CoV-2 mRNA lipid nanoparticle vaccines},
  journal = {Proceedings of the National Academy of Sciences},
  year = {2023},
  volume = {120},
  number = {33},
  doi = {10.1073/pnas.2303567120}
}
Kostenlos starten →